Comments
The shares of Natco Pharma Ltd gained over 3 per cent on Monday, after the company announced that it has received Emergency Use approval for Baricitinib tablets for Covid-19 treatment in India.
At 10:53 am, Natco Pharma was trading at ₹927.60 on the BSE, up ₹30.95 or 3.45 per cent. II hit an intra-day high of ₹935 and an intra-day low of ₹911.40. It had opened at ₹920 as against the previous close of ₹896.65.
Related Stories
Natco Pharma gets emergency nod for Baricitinib tablets to treat Covid-19
Baricitinib in combination with Remdesivir, is used for treatment of Covid positive patients.On the NSE , it was trading at ₹927.20, up 30.85 or 3.44 per cent.
The company on Monday announced that it has received Emergency Use approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from Central Drugs Standard Control Organization (CDSCO) in India.
“Baricitinib in combination with Remdesivir is used for the treatment of COVID-19 positive patients. Natco will be requesting a Compulsory License based on emergency use and in light of the grave and serious public health emergency across India due to the Pandemic,” the company said.
Natco is ready to launch the product this week, it further said.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.